LOTUSEYEHospital
Lotus Eye Hospital and Institute Ltd — Profit & Loss Statement
₹98.22
-2.47%
Lotus Eye Hospital and Institute Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 29400.00 | 16157.86 | -5014.80 | -0.01 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.27 | 0.28 | 0.27 | — |
| Normalized EBITDA | 4.73 Cr | 7.83 Cr | 8.73 Cr | 6.77 Cr | — |
| Total Unusual Items | 98000.00 | 59000.00 | -18000.00 | -0.05 Cr | — |
| Total Unusual Items Excluding Goodwill | 98000.00 | 59000.00 | -18000.00 | -0.05 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Reconciled Depreciation | 3.01 Cr | 3.73 Cr | 2.98 Cr | 2.50 Cr | — |
| Reconciled Cost Of Revenue | 24.90 Cr | 22.93 Cr | 22.73 Cr | 18.83 Cr | — |
| EBITDA | 4.74 Cr | 7.84 Cr | 8.73 Cr | 6.72 Cr | — |
| EBIT | 1.74 Cr | 4.11 Cr | 5.75 Cr | 4.22 Cr | — |
| Net Interest Income | -0.35 Cr | -0.10 Cr | 0.26 Cr | 0.22 Cr | — |
| Interest Expense | 0.35 Cr | 0.10 Cr | 0.10 Cr | 0.13 Cr | — |
| Normalized Income | 0.73 Cr | 2.91 Cr | 4.08 Cr | 3.02 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Total Expenses | 49.14 Cr | 45.41 Cr | 41.27 Cr | 34.62 Cr | — |
| Diluted NI Availto Com Stockholders | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Net Income Common Stockholders | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Net Income Including Noncontrolling Interests | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Net Income Continuous Operations | 0.74 Cr | 2.91 Cr | 4.08 Cr | 2.98 Cr | — |
| Tax Provision | 0.64 Cr | 1.10 Cr | 1.57 Cr | 1.11 Cr | — |
| Pretax Income | 1.38 Cr | 4.01 Cr | 5.65 Cr | 4.09 Cr | — |
| Other Non Operating Income Expenses | 1.30 Cr | 1.30 Cr | 0.68 Cr | 0.45 Cr | — |
| Special Income Charges | 98000.00 | 59000.00 | -18000.00 | -0.05 Cr | — |
| Net Non Operating Interest Income Expense | -0.35 Cr | -0.10 Cr | 0.26 Cr | 0.22 Cr | — |
| Interest Expense Non Operating | 0.35 Cr | 0.10 Cr | 0.10 Cr | 0.13 Cr | — |
| Operating Income | 0.43 Cr | 2.80 Cr | 4.71 Cr | 3.47 Cr | — |
| Operating Expense | 24.23 Cr | 22.48 Cr | 18.54 Cr | 15.79 Cr | — |
| Other Operating Expenses | 9.61 Cr | 8.94 Cr | 3.61 Cr | 3.08 Cr | — |
| Depreciation And Amortization In Income Statement | 3.01 Cr | 3.73 Cr | 2.98 Cr | 2.50 Cr | — |
| Depreciation Income Statement | 3.01 Cr | 3.73 Cr | 2.98 Cr | 2.50 Cr | — |
| Gross Profit | 24.66 Cr | 25.28 Cr | 23.26 Cr | 19.25 Cr | — |
| Cost Of Revenue | 24.90 Cr | 22.93 Cr | 22.73 Cr | 18.83 Cr | — |
| Total Revenue | 49.56 Cr | 48.21 Cr | 45.98 Cr | 38.09 Cr | — |
| Operating Revenue | 49.56 Cr | 48.21 Cr | 45.98 Cr | 38.09 Cr | — |
| Interest Income | — | 0.50 Cr | 0.47 Cr | 0.43 Cr | 0.39 Cr |
| Rent Expense Supplemental | — | 2.18 Cr | 2.05 Cr | 2.15 Cr | 2.01 Cr |
| Diluted Average Shares | — | 2.08 Cr | 2.08 Cr | 2.08 Cr | 2.08 Cr |
| Basic Average Shares | — | 2.08 Cr | 2.08 Cr | 2.08 Cr | 2.08 Cr |
| Diluted EPS | — | 1.40 | 1.96 | 1.44 | 0.75 |
| Basic EPS | — | 1.40 | 1.96 | 1.44 | 0.75 |
| Other Special Charges | — | -59000.00 | 18000.00 | 0.01 Cr | -0.08 Cr |
| Total Other Finance Cost | — | 0.10 Cr | 0.11 Cr | 0.09 Cr | 0.09 Cr |
| Interest Income Non Operating | — | 0.50 Cr | 0.47 Cr | 0.43 Cr | 0.39 Cr |
| Selling General And Administration | — | 1.97 Cr | 2.08 Cr | 1.57 Cr | 0.85 Cr |
| Selling And Marketing Expense | — | 1.28 Cr | 1.35 Cr | 1.00 Cr | 0.33 Cr |
| General And Administrative Expense | — | 0.69 Cr | 0.73 Cr | 0.57 Cr | 0.52 Cr |
| Rent And Landing Fees | — | 2.18 Cr | 2.05 Cr | 2.15 Cr | 2.01 Cr |
| Write Off | — | — | 0.00 | 0.04 Cr | 25000.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Lotus Eye Hospital and Institute Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.